Latest Shareholder Approval News

SGH Ltd and Steel Dynamics have jointly submitted a best and final offer of A$32.35 per share to acquire BlueScope Steel, valuing the company at A$15 billion and representing a significant premium over recent trading prices.

Identitii Limited faces a setback as Beauvais Capital terminates its underwriting agreement following Takeovers Panel orders, triggering shareholder withdrawal rights and uncertainty over the company’s capital raising plans.

Australian Bond Exchange Holdings has completed a $982,071 private placement, attracting new international and domestic investors to support its growth strategy.

Empire Resources has successfully raised nearly $2.9 million through the first tranche of its planned $5 million placement, with a second tranche pending shareholder approval in March.

Jayride Group Limited reports a narrower quarterly loss amid revenue challenges, secures $200,000 through convertible notes, and inks a new SaaS agreement with Thailand’s Drivemate to expand its mobility platform.

Stavely Minerals has locked in a $500,000 unsecured director loan facility to fund its 2026 Scoping Study targeting copper, gold, and silver production. This non-dilutive funding move underscores confidence from within the board as the company advances key projects.

Santana Minerals has raised A$130 million through a two-tranche placement and plans a share purchase plan to accelerate development of its Bendigo Ophir Gold Project. The equity raise aims to fund early works, exploration, and equipment procurement ahead of final resource consents.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Viva Leisure has announced a year-long on-market share buy-back program targeting up to 10% of its issued shares, aiming to capitalise on market volatility and reinforce its strong cash flow outlook.

Botanix Pharmaceuticals has launched a A$45 million capital raising to support the expansion of its dermatology product Sofdra®, while negotiating to reduce active pharmaceutical ingredient costs by up to 40%. The raising includes a two-tranche placement and a security purchase plan, with options offered to investors.

Botanix Pharmaceuticals has secured approximately A$45 million through a two-tranche placement and an underwritten security purchase plan to fund API purchases, derisk its supply chain, and accelerate growth of its flagship product Sofdra.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.